Assessment of ADCY5-related Movement Disorders With Motion SENSors

ADCY5-related Dyskinesia Clinical Trial

— SENSeo-ADCY5  

Official title:

Assessment of ADCY5-related Movement Disorders With Motion SENSors: a Feasibility Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05136495
• Other study ID #: APHP201439
• Secondary ID: 2021-A00994-37
• Status: Recruiting
• Phase: N/A
• Start date: July 4, 2024
• Est. completion date: July 4, 2024

Study information

• Verified date: January 2024
• Source: Assistance Publique - Hôpitaux de Paris
• Contact: louise laure MARIANI, MD, PhD
• Phone: 1 42 16 27 48
• Email: louise-laure.mariani[@]icm-institute.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

ADCY5-related movement disorders are caused by dominant mutations in the ADCY5 gene. This rare neurogenetic disease is characterized by childhood-onset generalized hyperkinetic movements. Currently, the only tools available to rate the severity of movement disorders observed in ADCY5-patients are clinical rating scales of abnormal movements. These scales use the investigators' judgement to rate globally the severity of movements observed in various body parts of the patient. This protocol proposes to investigate a multimodal approach, combining a clinical scale assessment with ViconTM's objective movement measurement. A secondary objective of the study is to assess the effect of coffee on ADCY5-patients.

Description:

ADCY5-related movement disorders are caused by dominant mutations in the ADCY5 gene. This rare neurogenetic disease is characterized by childhood-onset generalized hyperkinetic movements. The abnormal movements typically comprise a combination of dystonia, myoclonus and chorea occurring on a background of axial hypotonia, with superimposed disabling episodes of paroxysmal dyskinesia. The causing mutations are located in the ADCY5 gene coding for the Adenylate Cyclase 5 (AC5). AC5 is highly expressed in the striatal projection neurons of the striatum, a region involved in the control of movements. No effective treatment has been found. Currently, the only tools available to rate the severity of movement disorders observed in ADCY5-patients are clinical rating scales of abnormal movements. These scales use the investigators' judgement to globally rate movements severity in various body parts. This leads to inter-raters' scoring variability. An objective assessment through refined and comprehensive quantification of movements is needed. A motion capture system, such as ViconTM, could better reflect the global and focal variations of abnormal movements. This would be critical for the evaluation of responses to potential treatments. This protocol proposes to investigate a multimodal approach, combining a clinical scale assessment with ViconTM's objective movement measurement. A secondary objective of the study is to assess the effect of coffee on ADCY5-patients. The caffeine contained in coffee acts as a nonselective adenosine receptor antagonist, with a strong affinity for A2A receptors. By blocking A2A receptors, caffeine reduces the enzymatic activity of the altered mutated AC5 protein coded by the mutated ADCY5 gene. This effect could modulate the abnormal movements observed in patients.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 10
• Est. completion date: July 4, 2024
• Est. primary completion date: July 4, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 15 Years and older

Eligibility

Inclusion Criteria:

• ADCY5 mutation carriers

• Age > 15 years old and 3 months

• Informed consent from the patient or/ and a legal representative when appropriate

• Affiliated with a social security system or beneficiary of such a regime or by waiver from CPP ( french ethic committee) for patients outside the European union ( EU)

• daily caffeine consumer

Exclusion Criteria:

• Hypersensitivity to caffeine or to xanthine derivatives

• Heart condition contraindicating coffee intake

• Liver failure

• Impaired comprehension interfering with an informed consent

• Positive pregnancy test for women of childbearing potential

• Patient treated by Enoxacin, Ciprofloxacin, Norfloxacin (Noroxin), Cimetidine, Phenytoin ß-adrenergic drugs (ß2 mimetics) at inclusion.

Related Conditions & MeSH terms

• ADCY5-related Dyskinesia
• Dyskinesias
• Movement Disorders

Intervention

Other:
• caffeinated coffee - decaffeinated coffee
Drink caffeinated coffee one morning and drink decaffeinated coffee the other morning

Locations

Country	Name	City	State
France	CIC Neurosciences, GH Pitié-Salpêtrière	Paris

Sponsors (1)

Lead Sponsor	Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Quantification movement disorders	Assessment of correlation between displacement data using the ViconTM system and standardized clinical scales' scores of movements	24 HOURS
Secondary	Coffee effects	Change in abnormal movements, measured with motion sensors (ViconTM system) after caffeinated coffee vs after decaffeinated coffee	24 Hours
Secondary	Involuntary scales evaluation	Change in abnormal movements, measured with standardized clinical scale (Abnormal Involuntary Movement Scale (AIMS; Global score range 0 to 28 and severity subscore range 0 to 4; higher scores mean worse outcome), after caffeinated coffee vs after decaffeinated coffee	24 Hours
Secondary	Dyskinesia impairment evaluation	Change in abnormal movements, measured with standardized clinical scale Dyskinesia Impairment Scale (DIS) (total score range 0 to 288; higher scores mean worse outcome) after caffeinated coffee vs after decaffeinated coffee	24 Hours
Secondary	Dyskinesia Rating Scale evaluation	Change in abnormal movements, measured with standardized clinical scale Unified Dyskinesia Rating Scale (UDysRS) (total score range of 0 to 104; higher scores mean worse outcome), after caffeinated coffee vs after decaffeinated coffee	24 Hours